Editorial: Hemostasis and vascular dementia

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 3, 2010, Pages 461-463

  Bath, Philip M W ^a   Anderton, Peter R ^a   Ankolekar, Sandeep ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CLOPIDOGREL; D DIMER; DIPYRIDAMOLE; FIBRIN; FIBRINOGEN; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR; WARFARIN; BIOLOGICAL MARKER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ALZHEIMER DISEASE; ANTICOAGULATION; BLOOD CLOTTING; BLOOD PRESSURE; BRAIN CORTEX; BRAIN HEMORRHAGE; BRAIN VENTRICLE; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DETERIORATION; EDITORIAL; ENDOTHELIAL DYSFUNCTION; FIBRINOLYSIS; FOLLOW UP; HEMOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LEUKOARAIOSIS; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; RISK FACTOR; SIGNAL TRANSDUCTION; STROKE; THROMBIN TIME; VERBAL MEMORY; AGED; BLOOD; COGNITION; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COGNITION; DEMENTIA, VASCULAR; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; PROTHROMBIN;

EID: 77649146289     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.200824     Document Type: Editorial

References (18)

1. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009;8:1006-1018.
2. Paglieri C, Bisbocci D, Di Tullio MA, Tomassoni D, Amenta F, Veglio F. Arterial hypertension: a cause of cognitive impairment and of vascular dementia. Clin Exp Hypertens. 2004;26:277-285.
3. Moroney JT, Tang MX, Berglund L, Small S, Merchant C, Bell K, Stern Y, Mayeux R. Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA. 1999;282:254-260.
4. Lip GYH. Fibrinogen and cardiovascular disorders. Q J Med. 1995;88: 155-165.
5. Bath P, Algert C, Chapman N, Neal B; for the PROGRESS Collaborative Group. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke. 2004; 35:622-626.
6. Wilson CJ, Cohen JJ, Pieper CF. Cross-linked fibrin degradation products (D0Dimer), plasma cytokines, and cognitive decline in community-dwelling elderly persons. J Am Geriatr Soc. 2003;51:1374-1381.
7. Barber M, Tait RC, Scott J, Rumley A, Lowe GDO, Stott DJ. Dementia in subjects with atrial fibrillation: hemostatic function and the role of anticoagulation. J Thromb Haemost. 2004;2:1873-1878.
8. van Oijen M, Witteman JC, Hofman A, Koudstaal PJ, Breteler MB. Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke. 2005;36:2637-2641.
9. Rafnsson SB, Deary IJ, Smith FB, Whiteman MC, Rumley A, Lowe GDO, Fowkes GR. Cognitive decline and markers of inflammation and hemostasis: the Edinburgh Artery Study. J Am Geriatr Soc. 2007;55: 700-707.
10. Carcaillon L, Gaussem P, Ducimetière P, Giroud M, Ritchie K, Dartigues JF, Scarabin PY. Elevated plasma fibrin D-dimer as a risk factor for vascular dementia: the Three-City cohort study. J Thromb Haemost. 2009;7:1972-1978.
11. Lowe GDO. Is sticky blood a treatable determinant of cognitive decline and dementia. Age Ageing. 2001;30:101-103.
12. Stott DJ, Robertson MJ, Rumley A, Welsh P, Sattar N, Packard CJ, Shepherd J, Trompet S, Westendorp RGJ, de Craen AJM, Jukema W, Buckley B, Ford I, Lowe GDO. Activation of haemostasis and decline in cognitive function in older people. Arterioscler Thromb Vasc Biol. 2010; 30:605-611.
13. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Tworney C, Westendorp RG; for the PROSPER study group; PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-1630.
14. Gallacher J, Bayer A, Lowe G, Fish M, Pickering J, Pedro S, Dunstan F, White J, Yarnell J, Ben-Shlomo Y. Is sticky blood bad for the brain? hemostatic and inflammatory systems and dementia in the Caerphilly prospective study. Arterioscler Thromb Vasc Biol. 2010;30:599-604.
15. Ravaglia G, Forti P, Maioli F, Chiappelli M, Montesi F, Tumini E, Mariani E, Licastro F, Patterson C. Blood inflammatory markers and risk of dementia: the Conselice Study of Brain Aging. Neurobiol Ageing. 2007;28:1810-1820 (Pubitemid 47539699)
16. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol. 1997;42: 857-865.
17. Diener H-C, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton W, Palesch Y, Martin R, Albers GW, Bath PM, Bornstein N, Chan BPL, Chen S-T, Cunha L, Dahlof B, De Keyser J, Donnan GA, Estol C, Gorelick PB, Gu V, Hermansson K, Hillbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voight T, Weber M, Yoon B-W; for the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) Study Group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and tel-missartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008;7:875-884.
18. Greenberg SM, Vernooij MW, Cordonnier C, Viswanathian A, Al-Shahi Salman R, Warach S, Launer LJ, Van Buchem MA, Breteler MM; Microbleed Study Group. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol. 2009;8:165-174.